一种新型前列腺素E1制剂治疗勃起功能障碍的长期疗效。
Long-term efficacy of a new formulation of prostaglandin E1 as treatment for erectile failure.
作者信息
Godschalk M, Gheorghiu D, Chen J, Katz P G, Mulligan T
机构信息
Division of Geriatrics Medicine, Medical College of Virginia, McGuire Veterans Affairs Medical Center, Richmond, USA.
出版信息
J Urol. 1996 Mar;155(3):915-7.
PURPOSE
We determined the long-term efficacy of intracavernous injection of a new formulation of prostaglandin E1 (Caverject) as treatment for erectile failure.
MATERIALS AND METHODS
A prospective study was done at a university affiliated Veterans Affairs medical center. Subjects with erectile failure received injections of prostaglandin E1 at the office and self-administered injections at home for up to 18 months.
RESULTS
Of 16 patients who performed home injections 15 completed 6 months and 10 completed 18 months of therapy. Patient and spousal satisfaction with intercourse was 90% for months 1 to 6, and patient satisfaction was 95% for months 7 to 18.
CONCLUSIONS
Prostaglandin E1 was highly effective at producing penile rigidity and an erection with satisfactory vaginal intercourse.
目的
我们确定了海绵体内注射一种新配方的前列腺素E1（凯威捷）治疗勃起功能障碍的长期疗效。
材料与方法
在一所大学附属退伍军人事务医疗中心进行了一项前瞻性研究。勃起功能障碍患者在诊所接受前列腺素E1注射，并在家自行注射，为期长达18个月。
结果
16例进行家庭注射的患者中，15例完成了6个月的治疗，10例完成了18个月的治疗。第1至6个月患者及其配偶对性交的满意度为90%，第7至18个月患者满意度为95%。
结论
前列腺素E1在产生阴茎硬度及实现满意的阴道性交勃起方面非常有效。
Zotero 插件